Linc

Linc Interest Expense

The Interest Expense of Linc (LINC.ST) as of Nov 20, 2026 is 15.81 M SEK. In the previous year, Interest Expense was 20.46 M SEK — a change of -22.70% (lower).

Interest Expense

15.81 MSEK

YoY

-22.70%

Last updated:

Interest Expense of Linc is 2025 15.81 M SEK. Interest Expense of Linc was 2024 20.46 M SEK. It decreases by -22.70% lower compared to the previous year.

The Linc Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2018
1.20 M SEK
Jan 1, 2019
352,000.00 SEK
Jan 1, 2020
236,000.00 SEK
Jan 1, 2021
-958,000.00 SEK
Jan 1, 2022
2.52 M SEK
Jan 1, 2023
17.45 M SEK
Jan 1, 2024
20.46 M SEK
Jan 1, 2025
15.81 M SEK
The Linc Interest Expense history
YEARInterest ExpenseYoY
15.81 MSEK-22.70%
20.46 MSEK+17.22%
17.45 MSEK+593.92%
2.52 MSEK-362.53%
-958,000.00SEK-505.93%
236,000.00SEK-32.95%
352,000.00SEK-70.76%
1.20 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Linc Stock analysis

What does Linc do? Linc AB generates revenue through long-term share ownership in Nordic life science companies, focusing on pharmaceutical and medical technology sectors. The company invests in both private and public firms, including early-stage drug development and operational medical technology companies. Linc Invest actively supports portfolio companies by collaborating with management, founders, and boards to unlock growth potential and drive expansion. Its industrial network enables strategic participation in nomination committees and development planning. The firm targets Nordic life science product-oriented companies, prioritizing pharmaceuticals and medical technology. Investments span research and operational phases, with drug development typically occurring earlier than in medical technology. Linc AB maintains a hands-on approach as a long-term owner, leveraging its network to assist portfolio companies in achieving ambitious development goals. Linc AB's business model centers on active ownership and strategic partnerships within the Nordic life science ecosystem. It focuses on companies with strong product pipelines, particularly in pharmaceuticals, where investments often occur during initial development stages. The company's role as a supportive shareholder drives value creation through collaborative governance and targeted expansion strategies. Linc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Linc stock

Interest Expense of Linc is 15.81 M SEK in 2025.

Interest Expense of Linc changed from 20.46 M SEK to 15.81 M SEK, representing a -22.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Linc since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Linc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Linc

All Key Metrics — Linc